// App-Quantinova.ai

6511 : Efficacy and safety of bosutinib (BOS) for Philadelphia chromosomepositive (Ph+) leukemia in older versus younger patients (pts).

Researchers

Presenter

  • Tim H. Brummendorf

Principal Investigators

  • Carlo Gambacorti-Passerini

  • Philippe Schafhausen

  • Hanna Jean Khoury

  • Andreas Hochhaus

  • Thomas Kindler

  • Thomas Fischer

  • Nadine Besson

  • Eric Leip

  • Virginia Kelly

  • Jorge E. Cortes

Medical Centers

  • Universitaets-Klinikum Aachen, Universitaets-Klinikum Hamburg-Eppendorf, RWTH, Aachen & Hamburg, Germany

  • Emory University School of Medicine, Atlanta, GA

  • University of Milano-Bicocca, Monza, Italy

  • Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Universitatsklinikum Magdeburg, Magdeburg, Germany

  • Universitatsklinikum Jena, Jena, Germany

Locations

  • United States

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved